drugset / Trial / NCT05089708

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

NCT05089708

Phase 4 Completed 123 enrolled Galderma R&D
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle cream in the treatment of moderate acne vulgaris with risk of acne-induced post inflammatory hyperpigmentation (PIH) after 24 weeks of treatment in facial acne participants

Timeline

Start
2021-12-22
Primary completion
2022-12-15
Completion
2022-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 50 unknown Topical

Indications